CN102388067A - 定向于cd105的抗体及其用途 - Google Patents

定向于cd105的抗体及其用途 Download PDF

Info

Publication number
CN102388067A
CN102388067A CN2009801467390A CN200980146739A CN102388067A CN 102388067 A CN102388067 A CN 102388067A CN 2009801467390 A CN2009801467390 A CN 2009801467390A CN 200980146739 A CN200980146739 A CN 200980146739A CN 102388067 A CN102388067 A CN 102388067A
Authority
CN
China
Prior art keywords
antibody
seq
sequence
antibodies
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801467390A
Other languages
English (en)
Chinese (zh)
Inventor
J·巴布科克
S·T·巴里
G·加西特-伯恩斯坦
N·莱恩
Q·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Vaccines Inc
Original Assignee
MedImmune Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Vaccines Inc filed Critical MedImmune Vaccines Inc
Publication of CN102388067A publication Critical patent/CN102388067A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2009801467390A 2008-09-19 2009-09-18 定向于cd105的抗体及其用途 Pending CN102388067A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9868508P 2008-09-19 2008-09-19
US61/098,685 2008-09-19
PCT/GB2009/051216 WO2010032059A2 (en) 2008-09-19 2009-09-18 Targeted binding agents directed to cd105 and uses thereof

Publications (1)

Publication Number Publication Date
CN102388067A true CN102388067A (zh) 2012-03-21

Family

ID=41263674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801467390A Pending CN102388067A (zh) 2008-09-19 2009-09-18 定向于cd105的抗体及其用途

Country Status (9)

Country Link
US (1) US20100196398A1 (https=)
EP (1) EP2344541A2 (https=)
JP (1) JP2012502649A (https=)
KR (1) KR20110057245A (https=)
CN (1) CN102388067A (https=)
AU (1) AU2009294414A1 (https=)
BR (1) BRPI0918555A2 (https=)
CA (1) CA2737667A1 (https=)
WO (1) WO2010032059A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928359A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb59
CN106928355A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb184
CN108912212A (zh) * 2018-06-28 2018-11-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
CN112426526A (zh) * 2021-01-25 2021-03-02 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
WO2025045032A1 (zh) * 2023-08-29 2025-03-06 应世生物科技(南京)有限公司 一种靶向cd105的抗体或其抗原结合片段及其应用

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
CA2815181C (en) * 2010-10-27 2020-09-15 William Gleason Richards Dkk1 antibodies and methods of use
US9315582B2 (en) 2011-02-23 2016-04-19 Health Research, Inc. Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
EA201391248A1 (ru) * 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA2966905A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
SG11201802698XA (en) * 2015-10-29 2018-05-30 Hoffmann La Roche Transgenic rabbit with common light chain
US10729771B2 (en) 2016-02-10 2020-08-04 Rutgers, The State University Of New Jersey Anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of Mycobacterium tuberculosis infections
US20200239587A1 (en) * 2016-06-14 2020-07-30 Cedars-Sinai Medical Center Sensitization of tumors to therapies through endoglin antagonism
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021207433A2 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Epitopes of sars-cov-2 neutralizing antibodies
CN112876538B (zh) * 2021-02-04 2022-09-30 福建医科大学 靶向新生血管标记物cd105的多肽及其应用
US12162945B2 (en) 2021-03-05 2024-12-10 Immunome, Inc. EPHA2 antibodies
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20240135852A (ko) * 2022-01-24 2024-09-12 제노백 안티바디 디스커버리 엘엘씨 항-alk1 항체 및 그의 사용 방법
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
KR20250174161A (ko) * 2024-06-04 2025-12-12 한국과학기술연구원 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도
TWI882851B (zh) * 2024-06-27 2025-05-01 蔡政育 基於專利技術元素整合之專利分析系統及其方法
WO2026017807A1 (en) 2024-07-18 2026-01-22 Beech Biotech Sa Compositions and uses thereof
WO2026033033A1 (en) 2024-08-07 2026-02-12 Beech Biotech Sa Compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190660B1 (en) * 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKAHASHI N ET AL: "Antiangiogenic therapy of established tumors in human skin/severe combine immunodeficiency mouse chimeras by anti-endoglin（CD105） monoclonal antibodies，and synergy between anti-endoglin antibody and cyclophosphamide", 《CANCER RESEARCH》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928359A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb59
CN106928355A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb184
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN108912212A (zh) * 2018-06-28 2018-11-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
CN108912212B (zh) * 2018-06-28 2019-08-30 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
WO2020000634A1 (zh) * 2018-06-28 2020-01-02 中山大学附属口腔医院 一种与cd105特异性结合的多肽及其应用
CN112426526A (zh) * 2021-01-25 2021-03-02 北京达熙生物科技有限公司 一种nk细胞的制备方法及其在治疗癌症中的应用
WO2025045032A1 (zh) * 2023-08-29 2025-03-06 应世生物科技(南京)有限公司 一种靶向cd105的抗体或其抗原结合片段及其应用

Also Published As

Publication number Publication date
EP2344541A2 (en) 2011-07-20
WO2010032059A3 (en) 2010-06-24
CA2737667A1 (en) 2010-03-25
AU2009294414A1 (en) 2010-03-25
KR20110057245A (ko) 2011-05-31
JP2012502649A (ja) 2012-02-02
US20100196398A1 (en) 2010-08-05
WO2010032059A2 (en) 2010-03-25
BRPI0918555A2 (pt) 2016-05-03

Similar Documents

Publication Publication Date Title
JP6700447B2 (ja) Ｂ７−ｈ１に対する標的結合剤
CN102264763B (zh) 定向于dll4的抗体及其用途
CN102388067A (zh) 定向于cd105的抗体及其用途
US8119130B2 (en) Targeted binding agents directed to KDR and uses thereof—035
US8207306B2 (en) Targeted binding agents directed to sonic hedgehog homolog and uses thereof
CA2657898A1 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
JP2012513195A (ja) α５β１に向けられた標的化結合剤およびその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120321